Disease · MONDO_0002171
giant cell tumor
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. giant cell tumor. Diseases, record MONDO_0002171. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002171
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
giant cell neoplasm, giant cell tumor (morphologic abnormality), giant cell tumor (qualifier value), giant cell tumor NOS (morphologic abnormality), giant cell tumors (morphologic abnormality), giant cell tumour (morphologic abnormality), giant cell tumour (qualifier value), giant cell tumour NOS (morphologic abnormality), giant cell tumours (morphologic abnormality), tumor of the giant cell, tumour of the giant cell
- Open Targets
Drugs3
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| DENOSUMAB | CHEMBL1237023 | Antibody | Approval | DailyMed | 7 | 6 | 6 | Drugs and targets |
| NARLUMOSBART | CHEMBL5314993 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ZOLEDRONIC ACID | CHEMBL4303669 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets2
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| FDPS | Farnesyl pyrophosphate synthase | 1 | Farnesyl diphosphate synthase inhibitor | Phase 2 | https://conductscience.org/library/genes/2224 | Drugs and targets |
| TNFSF11 | Tumor necrosis factor ligand superfamily member 11 | 1 | Tumor necrosis factor ligand superfamily member 11 inhibitor | Approval | https://conductscience.org/library/genes/8600 | Drugs and targets |
Trials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00680992 | Study of Denosumab in Subjects With Giant Cell Tumor of Bone | Phase 2 | 535 | 2018-12-10 | Cancer, Giant Cell Tumors, Giant Cell Tumor of Bone, Benign Giant Cell Tumors | DENOSUMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT03301857 | Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 | Phase 4 | 85 | 2024-05-20 | Giant Cell Tumor of Bone | DENOSUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00396279 | Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone | Phase 2 | 37 | 2014-03-05 | GCT, Giant Cell Tumor of Bone | DENOSUMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT05813665 | A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone | Phase 3 | 146 | Giant Cell Tumor of Bone | DENOSUMAB, NARLUMOSBART | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT04586660 | Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone | Phase 4 | 36 | Giant Cell Tumor of Bone | DENOSUMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03259152 | Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone | Phase 3 | 30 | Giant Cell Tumor of Bone | DENOSUMAB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00889590 | Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT) | Phase 2 | 15 | Giant Cell Tumor of Bone, Osteoclastoma | ZOLEDRONIC ACID | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Exposed to IP vs Not Exposed to IP: deaths from any cause | 0 of 51 | 2 of 34 | 85 | NCT03301857 | Trial comparisons |
| Exposed to IP vs Not Exposed to IP: serious adverse events | 8 of 51 | 0 of 34 | 85 | NCT03301857 | Trial comparisons |
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002171
GET https://conductscience.org/api/diseases/v1/MONDO_0002171/drugs